Int. J. Mol. Sci. 2012, 13(7), 8670-8678; doi:10.3390/ijms13078670
Article

Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke

1email, 1email, 2email, 3email, 1,4email, 5,†email and 1,†,* email
Received: 7 May 2012; in revised form: 21 June 2012 / Accepted: 3 July 2012 / Published: 12 July 2012
(This article belongs to the Special Issue Neuroprotective Strategies 2012)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (p > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217–973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (p = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.
Keywords: ischemic stroke; monocyte chemoattractant protein-1 (MCP-1); antithrombotic therapy; neuroprotection; dipyridamole; acetylsalicylic acid (ASA)
PDF Full-text Download PDF Full-Text [291 KB, Updated Version, uploaded 19 June 2014 04:21 CEST]
The original version is still available [138 KB, uploaded 19 June 2014 04:21 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Worthmann, H.; Dengler, R.; Schumacher, H.; Schwartz, A.; Eisert, W.G.; Lichtinghagen, R.; Weissenborn, K. Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke. Int. J. Mol. Sci. 2012, 13, 8670-8678.

AMA Style

Worthmann H, Dengler R, Schumacher H, Schwartz A, Eisert WG, Lichtinghagen R, Weissenborn K. Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke. International Journal of Molecular Sciences. 2012; 13(7):8670-8678.

Chicago/Turabian Style

Worthmann, Hans; Dengler, Reinhard; Schumacher, Helmut; Schwartz, Andreas; Eisert, Wolfgang G.; Lichtinghagen, Ralf; Weissenborn, Karin. 2012. "Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke." Int. J. Mol. Sci. 13, no. 7: 8670-8678.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert